---
document_datetime: 2026-01-15 12:46:00
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/roclanda-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: roclanda-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6058891
conversion_datetime: 2026-01-17 13:31:13.779605
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Roclanda

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                      |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------|
| Variation type IB /  | This was an application for a variation | 15/01/2026                          | N/A                                         |                                  | To update the RMP by removing the PASS study |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000290523                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (Type IB) - To update the RMP by removing the PASS study from the RMP, as agreed during the MEA 001.6 (EMA/PAM/0000272898) procedure.   |            |            |                                  | from the RMP, as agreed during the MEA 001.6 (EMA/PAM/0000272898) procedure.                                                                                                                                                                                           |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 5 year / EMA/R/0000255956   | - Renewal - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 19/06/2025 | 14/08/2025 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Roclanda in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| Variation type IB / EMA/VR/0000246584 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer                                                                                                                                                            | 13/03/2025 | N/A        |                                  |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|